Search Results
Your search for ,ARE matches 21644 pages
Showing 3201 - 3250CLL2-GIVe Trial: Regimen of Obinutuzumab, Ibrutinib, and Venetoclax Effective in High-Risk CLL
The first-line combination of obinutuzumab, ibrutinib, and venetoclax appears to be effective in treating high-risk chronic lymphocytic leukemia (CLL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.1 Results of the CLL2-GIVe trial, which...
Expert Point of View: Emily K. Curran, MD
Moderator of the session, Emily K. Curran, MD, Assistant Professor of Internal Medicine at the University of Cincinnati Cancer Center, in Ohio, said the data presented by Dr. Short and colleagues demonstrated very impressive event-free and overall survival rates, especially for a disease that has...
Ponatinib and Blinatumomab Combination Safe and Effective in Patients With Newly Diagnosed, Ph-Positive ALL
The combination of ponatinib and blinatumomab has led to rapid and durable remissions in patients with newly diagnosed Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to data presented at the 2022 American Society of Hematology (ASH) Annual Meeting and...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Amir T. Fathi, MD
Amir T. Fathi, MD, Associate Professor of Medicine at Harvard Medical School and Director of the Leukemia Program at Massachusetts General Cancer Center, said the approach of intensifying chemotherapy with the addition of venetoclax is one of several being studied in the upfront setting....
Expert Point of View: Catherine S. Diefenbach, MD
Catherine S. Diefenbach, MD, Associate Professor at NYU Grossman School of Medicine, Director of the Clinical Lymphoma Program, and Director of Hematology Translational Research at Perlmutter Cancer Center, in New York, called the findings from the TRANSFORM trial “very striking.” “This study...
Addition of Venetoclax to Intensive Chemotherapy Yields Durable Responses in Younger Patients With High-Risk AML
Longer follow-up of a phase II study of venetoclax combined with cladribine, idarubicin, and cytarabine (CLIA) as a front-line induction regimen for younger patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) shows a pattern of durable efficacy consistent with...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Expert Point of View: Alexey Danilov, MD, PhD
Alexey Danilov, MD, PhD, Co-Director, Toni Stephenson Lymphoma Center and Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, commented on the phase III ALPINE trial comparing ibrutinib and zanubrutinib in patients...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Mrinal S. Patnaik, MBBS
Mrinal S. Patnaik, MBBS, Chair of the Acute Leukemia and Myeloid Neoplasms Group and Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program at the Mayo Clinic, Rochester, Minnesota, offered his thoughts on the phase II study findings of ruxolitinib’s efficacy...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Expert Point of View: Mikkael Sekeres, MD
“Standard treatment of older or less fit adults with acute myeloid leukemia (AML) is now venetoclax/azacitidine, which has been shown to improve overall survival vs azacitidine monotherapy. Since that backbone was established, there has been a tsunami of trials looking at drugs added to this...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Highlights From the 2022 ASH Annual Meeting and Exposition
The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition took place in the vibrant city of New Orleans. The meeting brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from hypothesis-generating to...
Ponatinib May Be More Effective Than Imatinib for Newly Diagnosed Patients With Ph-Positive ALL
In newly diagnosed patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy. These results were presented by Jabbour et al during the February ASCO Plenary Series session...
Is a Diet Higher in Plant-Based Foods Associated With a Lower Risk of Prostate Cancer Progression and Recurrence?
Patients with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of disease progression and a 53% lower risk of recurrence compared with those who had the lowest amounts of plants in their diets. The diet assessments were based on...
New Study Calls for LGBTQIA+ Community Inclusion in Stem Cell Donor Recruitment
Researchers have highlighted the barriers to stem cell donation impacting LGBTQIA+ individuals and the efforts needed to build more inclusive donor recruitment practices and offered guidance for donor recruitment organizations, registries, and transplant centers worldwide to advance a more...
Decline in PSA Level After Treatment With Enzalutamide: Effect on Metastasis and Survival
A decline in prostate-specific antigen (PSA) levels following treatment with the androgen receptor inhibitor enzalutamide may effectively predict improved survival rates among patients with nonmetastatic castration-resistant prostate cancer, according to a post hoc analysis of data from the PROSPER ...
New Predictive Epidemiologic Model May Identify Individuals at High Risk for Endometrial Cancer
Investigators have developed a predictive model that may be used in research and eventually clinical settings to identify individuals at high risk of developing endometrial cancer who would benefit from screenings, according to a report published by Shi et al in the Journal of the National Cancer...
Pancreatic Cancer Rates May Be Rising Faster Among Younger Women Than Younger Men
Investigators have confirmed that rates of pancreatic cancer are rising overall, but they are rising faster among younger female patients—particularly among patients who identified as Black—than among male patients of the same age, according to a new study published by Abboud et al in...
Lack of Resources May Be Associated With Increased Mortality Rates Among Pediatric Cancer Survivors
Investigators have found that socioeconomic deprivation, the presence of modifiable chronic health conditions, and frailty may all independently be associated with increased rates of late mortality among pediatric cancer survivors, according to a new study published by Ehrhardt et al in JAMA...
Dietary Intervention May Help Reduce Chronic Fatigue, Improve Quality of Life for Cancer Survivors
Researchers have discovered that dietary interventions may help reduce fatigue, improve diet quality, and lead to an overall better quality of life for cancer survivors, according to a new study published by Weinhold et al in Nutrition and Cancer. Background For many cancer survivors, the side...
Focal vs Extended Irreversible Electroporation in Ablation of Localized Low- or Intermediate-Risk Prostate Cancer
In a study reported in JAMA Surgery, Zhang et al found that focal and extended irreversible electroporation (IRE) produced similar results in the ablation of low- or intermediate-risk prostate cancer. Study Details In the study, 106 patients from five European centers were randomly assigned between ...
FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
On February 9, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or...
Continued Declines in Cancer Mortality and Reductions in Cervical Cancer Incidence, but Increases in Advanced Prostate Cancer and Persistent Racial Disparities
The American Cancer Society (ACS) has released its Cancer Statistics 2023 report, which showed that overall cancer mortality has dropped by 33% since 1991, averting an estimated 3.8 million cancer deaths, according to the report. Data in the report also showed that women between the ages of 20 and...
Acupuncture for Chemotherapy-Induced Peripheral Neuropathy: Health-Related Quality-of-Life Outcomes From a Randomized Clinical Trial
Guest Editor’s Note: Chemotherapy-induced peripheral neuropathy is a common and potentially debilitating side effect of neurotoxic chemotherapy. It worsens the quality of life for many cancer survivors, with limited treatment options. In this installment of The ASCO Post’s Integrative Oncology...
The Beauty and the Beast of Cancer
The most humbling—and fortunate—experience I’ve had since I was diagnosed with osteosarcoma 13 years ago at the age of 43 was being treated in the pediatric wing of a major cancer center in New York City. It is pretty difficult to feel sorry for yourself when you are sitting next to a 14-year-old...
Raised in Africa, Surgeon Kristin Flowers, MD, Continues the Tradition of Service in a Rural Hospital in Alaska
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Kristin Flowers, MD, a general surgeon at Tanana Valley Clinic at Fairbanks Memorial Hospital in rural Alaska. Dr. Flowers’ surgical areas of interest include treating...
Traveling the World at an Early Age Gave Perspective and Balance to Future Oncology Leader Derek Raghavan, MD, PhD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Founding President of the Levine Cancer Institute. Established in 2011, the Levine Cancer Institute is part of Atrium Health (formerly the...
MD Anderson’s Guillermina Lozano, PhD, Receives AAMC Award for Distinguished Research in the Biomedical Sciences
In recognition of her work in uncovering the mechanisms of the p53 tumor suppressor, Guillermina “Gigi” Lozano, PhD, Chair of Genetics at The University of Texas MD Anderson Cancer Center, Houston, has received the 2022 Award for Distinguished Research in the Biomedical Sciences by the Association...
Common Immune-Related Adverse Events: Spotlight on Gastrointestinal and Hepatic Toxicities
At the inaugural MD Anderson Clinical Education Symposium on Immunotherapy Organ Toxicity Management (IOTOX), a panel of experts discussed common immune-related adverse events associated with immune checkpoint inhibitor therapy, including gastrointestinal (GI), hepatic, dermatologic, pulmonary, and ...
Terry Hyslop, PhD, Joins SKCC as Cancer Risk and Control Program Co-Leader and Center for Health Equity Director
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently welcomed transdisciplinary population health researcher Terry Hyslop, PhD, as Co-Leader of the Cancer Risk and Control Program. Dr. Hyslop is returning to SKCC from the Duke Cancer Institute, where she served as Professor of...
KRYSTAL-1 Confirms Activity of Adagrasib in KRAS G12C–Mutated Metastatic Colorectal Cancer and Highlights Need for Randomized Controlled Trials
KRAS G12C–mutated colorectal cancer represents 3% to 4% of metastatic colorectal cancers. Like other KRAS-mutated metastatic colorectal cancers, this group of patients represents a patient population with an unmet need, with limited options beyond two lines of therapy. In contrast to other KRAS...
New JCO Oncology Practice Special Series Highlights Current State of Team-Based Care, Innovations, and Future Direction
What is team-based cancer care, and how has it evolved over the past decade? A special series in ASCO’s JCO Oncology Practice highlights transformations in team-based delivery models within the cancer care system and their potential direction. A carefully curated series of 15 peer-reviewed articles ...
ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer
A new ASCO guideline is available on the use of immunotherapy and biomarker testing for patients with recurrent or metastatic head and neck squamous cell carcinoma. The guideline provides recommendations related to PD-L1 and tumor mutational burden (TMB) testing, selection of therapy in the...
ASCO Formalizes Free Membership for Physicians in Lower-Middle–Income Countries
The ASCO Board of Directors recently took further action to support members in lower-middle–income countries. In alignment with ASCO’s strategic goal of making a global impact, the Board elected to expand free membership for physicians from lower-middle–income countries, as defined by the World...
Quick Takes on Important Cancer Research From ASH 2022
The high-energy vibe at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition reflected the welcomed presence of enthusiastic on-site attendees and the high quality of the research presented. The ASCO Post has already reported in detail on many of these presentations, and now...
Expert Point of View: Julio C. Chavez, MD
Julio C. Chavez, MD, Associate Member in the Lymphoma Section of the Department of Malignant Hematology at Moffitt Cancer Center, Tampa, who co-moderated the session where the glofitamab study was presented, shared his thoughts with The ASCO Post. “Glofitamab has great activity in high-risk...
Complete Response to Glofitamab at End of Treatment Heralds Prolonged Remission in Lymphoma
Patients with large B-cell lymphoma who achieve a complete response to glofitamab are very likely to remain in remission 12 months after the end of treatment, according to Martin Hutchings, MD, PhD, of Rigshospitalet in Copenhagen, who reported these findings at the 2022 American Society of...
Expert Point of View: Maryam B. Lustberg, MD, MPH
Maryam B. Lustberg, MD, MPH, Chief of Breast Medical Oncology at Yale Cancer Center, New Haven, shared her thoughts on TROPiCS-02 with The ASCO Post. “The progression-free survival and overall survival results of the phase III TROPiCS-02 trial position sacituzumab govitecan-hziy as an important...
Is Efficacy of Sacituzumab Govitecan-hziy in the TROPiCS-02 Trial Dependent on Trop-2 Expression?
The latest analysis of the TROPiCS-02 breast cancer trial showed that the antibody-drug conjugate sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio Breast Cancer Symposium by Hope S. Rugo, MD, FASCO, ...
Expert Point of View: Virginia Kaklamani, MD, Lori J. Pierce, MD, FASTRO, FASCO, and Eric Winer, MD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at UT Health San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, said the findings from RxPONDER and those regarding the tumor microenvironment of metastasis (TMEM) doorway are ...
Despite Similar Recurrence Scores, Breast Cancer Outcomes Differ by Race
Suboptimal treatment, which often underlies worse outcomes for cancer in racial minorities, did not explain a recent finding from the landmark RxPONDER study: non-Hispanic Black women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer had worse outcomes compared with...
Expert Point of View: Polly Niravath, MD and Virginia Kaklamani, MD
The invited discussant of the SOFT analysis was Polly Niravath, MD, Associate Professor and Director of the Cancer Survivorship Program at Houston Methodist Hospital in Texas. She noted that the study evaluated the use of the Breast Cancer Index (BCI) as a prognostic tool in early hormone...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
